Literature DB >> 24114468

[Foot lesions].

C Stelzner1, S Schellong, U Wollina, J Machetanz, L Unger.   

Abstract

The foot is the target organ of a variety of internal diseases. Of upmost importance is the diabetic foot syndrome (DFS). Its complex pathophysiology is driven by the diabetic neuropathy, a vastly worsening effect is contributed by infection and ischemia. Seemingly localised lesions have the potential for phlegmone and septicaemia if not diagnosed and drained early. The acral lesions of peripheral artery occlusive disease (PAOD) have unique features as well. However, their life-threatening potential is lower than that of DFS even if the limb is critical. Notably, isolated foot lesions with a mere venous cause may arise from insufficient perforator veins; the accompanying areas of haemosiderosis will lead the diagnostic path. Cholesterol embolization (blue toe syndrome, trash foot) elicits a unique clinical picture and will become more frequent with increasing numbers of catheter-based procedures. Finally, descriptions are given of podagra and of foot mycosis as disease entities not linked to perfusion. The present review focuses on the depiction of disease and its diagnosis, leaving therapeutic considerations untouched.

Entities:  

Mesh:

Year:  2013        PMID: 24114468     DOI: 10.1007/s00108-013-3343-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Dual energy CT in gout: a prospective validation study.

Authors:  Hyon K Choi; Lindsay C Burns; Kamran Shojania; Nicole Koenig; Graham Reid; Mohammed Abufayyah; Genevieve Law; Alison S Kydd; Hugue Ouellette; Savvas Nicolaou
Journal:  Ann Rheum Dis       Date:  2012-03-02       Impact factor: 19.103

2.  Reflux in foot veins is associated with venous toe and forefoot ulceration.

Authors:  Paul S van Bemmelen; Daniel Spivack; Patrick Kelly
Journal:  J Vasc Surg       Date:  2010-11-03       Impact factor: 4.268

Review 3.  Clinical practice. Fungal nail disease.

Authors:  David de Berker
Journal:  N Engl J Med       Date:  2009-05-14       Impact factor: 91.245

Review 4.  A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia.

Authors:  Priya V Chowalloor; Helen Isobel Keen
Journal:  Ann Rheum Dis       Date:  2013-01-03       Impact factor: 19.103

5.  The diagnostic value of the proposal for clinical gout diagnosis (CGD).

Authors:  Janitzia Vázquez-Mellado; Claudia B Hernández-Cuevas; Everardo Alvarez-Hernández; Lucio Ventura-Rios; Ingris Peláez-Ballestas; Julio Casasola-Vargas; Sergio García-Méndez; Rubén Burgos-Vargas
Journal:  Clin Rheumatol       Date:  2011-10-07       Impact factor: 2.980

6.  [Diabetic foot syndrome].

Authors:  R Lobmann
Journal:  Internist (Berl)       Date:  2011-05       Impact factor: 0.743

Review 7.  Chapter I: Definitions, epidemiology, clinical presentation and prognosis.

Authors:  F Becker; H Robert-Ebadi; J-B Ricco; C Setacci; P Cao; G de Donato; H H Eckstein; P De Rango; N Diehm; J Schmidli; M Teraa; F L Moll; F Dick; A H Davies; M Lepäntalo; J Apelqvist
Journal:  Eur J Vasc Endovasc Surg       Date:  2011-12       Impact factor: 7.069

8.  [Diabetic foot syndrome from the perspective of angiology and diabetology].

Authors:  H Lawall; C Diehm
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

9.  Blue (or purple) toe syndrome.

Authors:  Jan V Hirschmann; Gregory J Raugi
Journal:  J Am Acad Dermatol       Date:  2009-01       Impact factor: 11.527

10.  The Charcot foot in diabetes.

Authors:  Lee C Rogers; Robert G Frykberg; David G Armstrong; Andrew J M Boulton; Michael Edmonds; Georges Ha Van; Agnes Hartemann; Frances Game; William Jeffcoate; Alexandra Jirkovska; Edward Jude; Stephan Morbach; William B Morrison; Michael Pinzur; Dario Pitocco; Lee Sanders; Dane K Wukich; Luigi Uccioli
Journal:  Diabetes Care       Date:  2011-09       Impact factor: 19.112

  10 in total
  1 in total

Review 1.  [The conspicuous leg].

Authors:  S M Schellong
Journal:  Internist (Berl)       Date:  2018-03       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.